Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

SOMERVILLE, Mass., April 16, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd.

Bluebird Bio (BLUE) announced that after three weeks of engagement, including a timeline extension, Ayrmid has not submitted a binding proposal ...

--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd ...

(RTTNews) - Bluebird bio, Inc. (BLUE), the Massachusetts based biotechnology company, on Wednesday announced that after three weeks of discussions and an extended deadline Ayrmid Ltd. has not made ...

“Ayrmid’s proposal remains highly conditional, despite an extension to the previously agreed-upon timeline to complete confirmatory diligence and submit a binding offer,” said Mark ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track ...

Bluebird (Nasdaq: BLUE) said its board unanimously recommended going forward with the acquisition offer from Carlyle and SK ...